Lipid based nanoemulsifying resveratrol for improved physicochemical characteristics, in vitro cytotoxicity and in vivo antiangiogenic efficacy

Colloids and Surfaces B: Biointerfaces

Volumn 120, Issue , 2014, Pages 110-117

  Pund, Swati ^a   Thakur, Rohit ^a   More, Umesh ^a   Joshi, Amita ^b  

^a Sinhgad Institute of Pharmacy   (India)

^b B V PATEL PHARMACEUTICAL EDUCATION AND RESEARCH DEVELOPMENT PERD CENTRE   (India)

Author keywords

Antiangiogenic; Cytotoxicity; Nanoemulsion; Resveratrol; Solubility

Indexed keywords

BIOCHEMISTRY; CHEMOTHERAPY; CYTOTOXICITY; EMULSIFICATION; SOLUBILITY; SURFACE ACTIVE AGENTS;

ANTI-ANGIOGENIC ACTIVITY; ANTIANGIOGENIC; CHICK CHORIOALLANTOIC MEMBRANE; MCF-7 BREAST CANCER CELLS; NANOEMULSION; NEGATIVE ZETA POTENTIALS; PHYSICOCHEMICAL CHARACTERISTICS; PSEUDOTERNARY PHASE DIAGRAMS;

RESVERATROL;

DIETHYLENE GLYCOL MONOETHYL ETHER; LABRASOL; LIPID; RESVERATROL; ALUMINUM DERIVATIVE; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; ATTAPULGITE; EMULSION; ETHYLENE GLYCOL DERIVATIVE; MAGNESIUM DERIVATIVE; ORGANIC COMPOUND; SILICATE; STILBENE DERIVATIVE;

ANIMAL EXPERIMENT; ANTIANGIOGENIC ACTIVITY; ARTICLE; CANCER INHIBITION; CHICK EMBRYO; CHORIOALLANTOIS; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG SOLUBILITY; DRUG STABILITY; EMBRYO; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MCF 7 CELL LINE; NANOEMULSION; NONHUMAN; PRIORITY JOURNAL; THERMOSTABILITY; ZETA POTENTIAL; ANIMAL; CELL DEATH; CELL PROLIFERATION; CELL SURVIVAL; CHEMISTRY; CHICKEN; DRUG DELIVERY SYSTEM; DRUG EFFECTS; EMULSION; PARTICLE SIZE; PH; PHASE TRANSITION; PHYSICAL CHEMISTRY; SOLUBILITY; STATIC ELECTRICITY; THERMODYNAMICS;

ALUMINUM COMPOUNDS; ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; CELL DEATH; CELL PROLIFERATION; CELL SURVIVAL; CHICKENS; CHORIOALLANTOIC MEMBRANE; DRUG DELIVERY SYSTEMS; EMULSIONS; ETHYLENE GLYCOLS; HUMANS; HYDROGEN-ION CONCENTRATION; LIPIDS; MAGNESIUM COMPOUNDS; MCF-7 CELLS; ORGANIC CHEMICALS; PARTICLE SIZE; PHASE TRANSITION; PHYSICOCHEMICAL PHENOMENA; SILICATES; SOLUBILITY; STATIC ELECTRICITY; STILBENES; THERMODYNAMICS;

EID: 84901759449     PISSN: 09277765     EISSN: 18734367     Source Type: Journal    
DOI: 10.1016/j.colsurfb.2014.05.016     Document Type: Article

References (38)

1. Siegel R., Naishadham D., Jemal A. Cancer statistics 2012. CA: Cancer J. Clin. 2012, 62:10-29.
2. Cunnick G.H., Jiang W.G., Gomez K.F., Mansel R.E. Lymphangiogenesis and breast cancer metastasis. Histol. Histopathol. 2002, 17:863-870.
3. He Y., Karpanen T., Alitalo K. Role of lymphangiogenic factors in tumor metastasis. Biochim. Biophys. Acta 2004, 1654:3-12.
4. Nair H.B., Sung B., Yadav V.R., Kannappan R., Chaturvedi M.M., Aggarwal B.B. Delivery of antiinflammatory nutraceuticals by nanoparticles for the prevention and treatment of cancer. Biochem. Pharmacol. 2010, 80:1833-1843.
5. Athar M., Back J.H., Tang X., Kim K.H., Kopelovich L., Bickers D.R., Kim A.L. Resveratrol: a review of preclinical studies for human cancer prevention. Toxicol. Appl. Pharmacol. 2007, 224:274-283.
6. Kasiotis K.M., Pratsinis H., Kletsas D., Haroutounian S.A. Resveratrol and related stilbenes: their anti-aging and anti-angiogenic properties. Food Chem. Toxicol. 2013, 61:112-120.
7. Amri A., Sfar J.C.S., Charrueau C. Administration of resveratrol: what formulation solutions to bioavailability limitations?. J. Control. Release 2012, 158:182-193.
8. Bharali D.J., Siddiqui I.A., Adhami V.M., Chamcheu J.C., Aldahmash A.M., Mukhtar H., Mousa S.A. Nanoparticle delivery of natural products in the prevention and treatment of cancers: current status and future prospects. Cancers 2011, 3:4024-4045.
9. Pouton C.W., Porter C.J.H. Enhancing intestinal drug solubilisation using lipid-based delivery systems. Adv. Drug Delivery Rev. 2008, 60:625-637.
10. Shete H., Patarvale V. Long chain lipid based tamoxifen NLC. Part I: Preformulation studies, formulation development and physicochemical characterization. Int. J. Pharm. 2013, 454:573-583.
11. C.W. Pouton, C.J.H. Porter, Formulation of lipid-based delivery systems for oral administration: Materials, methods and strategies. Adv. Drug Deliv. Rev. 60 (2008) 625-637.
12. Setthacheewakul S., Mahattanadul S., Phadoongsombut N., Pichayakorn W., Wiwattanapatapee R. Development and evaluation of self-microemulsifying liquid and pellet formulations of curcumin, and absorption studies in rats. Eur. J. Pharm. Biopharm. 2010, 76:475-485.
13. Pund S., Borade G., Rasve G. Improvement of anti-inflammatory and anti-angiogenic activity of berberine by novel rapid dissolving nanoemulsifying technique. Phytomedicine 2014, 21:307-314.
14. Zimmerman E., Müller R.H. Electrolyte- and pH-stabilities of aqueous solid lipid nanoparticle (SLN™) dispersions in artificial gastrointestinal media. Eur. J. Pharm. Biopharm. 2001, 52:203-210.
15. Kallakunta V.R., Bandari S., Jukanti R., Veerareddy P.R. Oral self emulsifying powder of lercanidipine hydrochloride: formulation and evaluation. Powder Technol. 2012, 221:375-382.
16. Skehn P., Storeng R., Scudiero D., Monks A., McMohan J., Vistica D., Warren J.T., Bokesch H., Kenney S., Boyd M.R. New colorimetric cytotoxicity assay for anticancer-drug screening. J. Nat. Cancer Inst. 1990, 82:1107-1112.
17. Jung H.J., Jeon H.J., Lim E.J., Ahn E.K., Song Y.S., Lee S., Shin K.H., Lim C.J., Park E.H. Anti-angiogenic activity of the methanol extract and its fractions of Ulmus davidiana var. japonica. J. Ethnopharmacol. 2007, 112(2007):406-409.
18. Seow L.J., Beh H.K., Majid A.M.S.A., Murugaiyah V., Ismail N., Asmawi M.Z. Anti-angiogenic activity of Gynura segetum leaf extracts and its fractions. J. Ethnopharmacol. 2011, 134:221-227.
19. Song Y.S., Kim S.H., Sa J.H., Jin C., Lim C.J., Park E.H., Antiangiogenic E.H. inhibitory activity on inducible nitric oxide production of the mushroom Ganoderma lucidum. J. Ethnopharmacol. 2004, 90:17-20.
20. Bürgermeister J., Paper D.H., Vogl H., Linhardt R.J., Franza G. LaPSvS1, a (1→3)-β-galactan sulfate and its effect on angiogenesis in vivo and in vitro. Carbohydr. Res. 2002, 337:1459-1466.
21. Krenn L., Paper D.H. Inhibition of angiogenesis and inflammation by an extract of red clover (Trifolim pratense L.). Phytomedicine 2009, 16:1083-1088.
22. Kundu J.K., Surh Y.J. Cancer chemopreventive and therapeutic potential of resveratrol: mechanistic perspectives. Cancer Lett. 2008, 269:243-261.
23. Atanacković M.T., Gojković-Bukarica L.C., Cvejić J.M. Improving the low solubility of resveratrol. BMC Pharmacol. Toxicol. 2012, 13:A25.
24. Jang M., Cai L., Udeani G.O., Slowing K.V., Thomas C., Beecher C.W.W., Fong H.H.S., Farnsworth N.R., Kingborn A.D., Mehta R.G., Moon R.C., Pezzuto J.M. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 1997, 275:218-220.
25. Kumpugdee-Vollrath M., Ibold Y. Increasing solubility of poorly water soluble drug resveratrol by surfactants and cyclodextrins. Adv. Mater. Res. 2012, 418-420:2231-2234.
26. Amri A., Le Clanche S., Thérond P., Bonnefont-Rousselot D., Borderie D., Lai-Kuen R., Chaumeil J-C., Sfar S., Charrueau C. Resveratrol self-emulsifying system increases the uptake by endothelial cells and improves protection against oxidative stress-mediated death. Eur. J. Pharm. Biopharm. 2013, doi: http://dx.doi.org/10.1016/j.ejpb.2013.10.015.
27. Narayanan N.K., Nargi D., Randolph C., Narayanan B.A. Liposome encapsulation of curcumin and resveratrol in combination reduces prostate cancer incidence in PTEN knockout mice. Int. J. Cancer 2009, 125:1-8.
28. Sessa M., Balestrieri M.L., Ferrari G., Servillo L., Castaldo D., D'Onofrio N., Donsì F., Tsao R. Bioavailability of encapsulated resveratrol into nanoemulsion-based delivery systems. Food Chem. 2014, 147:42-50.
29. Pouton C.W. Lipid formulations for oral administration of drugs: non-emulsifying, self-emulsifying and self-microemulsifying drug delivery systems. Eur. J. Pharm. Sci. 2000, 11:S93-S98.
30. Sha X., Yan G., Wu Y., Li J., Fang X. Effect of self-microemulsifying drug delivery systems containing Labrasol on tight junctions in Caco-2 cells. Eur. J. Pharm. Sci. 2005, 24:477-486.
31. Balakrishnan P., Lee B-J., Oh D.H., Kim J.O., Hong M.J., Jee J-P., Kim J.A., Yoo B.K., Woo J.S., Yong C.S., Choi H-G. Enhanced oral bioavailability of dexibuprofen by a novel solid self-emulsifying drug delivery system (SEDDS). Eur. J. Pharm. Biopharm. 2009, 72:539-545.
32. Singh A.K., Chaurasiya A., Singh M., Upadhyay S.C., Mukherjee R., Khar R.K. Exemestane loaded self-microemulsifying drug delivery system (SMEDDS): development and optimization. AAPS PharmSciTech 2008, 9:628-634.
33. Pund S., Shete Y., Jagadale S. Multivariate analysis of physicochemical characteristics of lipid based nanoemulsifying cilostazol-quality by design. Colloids Surf., B: Biointerfaces 2014, 115:29-36.
34. Rao J., McClements D.J. Optimization of lipid nanoparticle formation for beverage applications: influence of oil type, cosolvents, and cosurfactants on nanoemulsion properties. J. Food Eng. 2013, 118:198-204.
35. Gershanik T., Benzeno S., Benita S. Interaction of a self-emulsifying lipid drug delivery system with the everated rat intestinal mucosa as a function of droplet size and surface charge. Pharm. Res. 1998, 15:863-869.
36. Zhao Y., Wang C., Chow A.H.L., Ren K., Gong T., Zhang Z., Zheng Y. Self nanoemulsifying drug delivery system (SNEDDS) for oral delivery of Zedoary essential oil: Formulation and bioavailability studies. Int. J. Pharm. 2010, 383:170-177.
37. Itoh K., Tozuka Y., Oguchi T., Yamamoto K. Improvement of physicochemical properties of N-4472 part I formulation design by using self-microemulsifying system. Int. J. Pharm. 2002, 238:153-160.
38. Larger E., Marre M., Corvol P., Gasc J-M. Hyperglycemia-induced defects in angiogenesis in the chicken chorioallantoic membrane model. Diabetes 2004, 53:752-761.